ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 24 Issue : 2
Current Issue Archive Popular Article Ahead of Print

 
Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(4): 310-313 | DOI: 10.5152/akd.2011.081  

Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial

Okan Erdoğan1, Bülent Ertem2, Armağan Altun3
1Department of Cardiology, Faculty of Medicine, University of Marmara, İstanbul
2Department of Cardiology, Faculty of Medicine, Trakya University, Edirne
3Department of Cardiology, Trakya University School of Medicine, Edirne, Turkey

Objective: The aim of the present study is to compare the antihypertensive effects of carvedilol and nebivolol in mild to moderate hypertensive patients. Methods: It is a prospective; placebo-controlled, cross-over, double-blind, randomized, single-center clinical trial. Patients (n=20) who were first diagnosed with mild to moderate systemic hypertension according to mean ambulatory blood pressure measurements > 130/85 mmHg and no previous antihypertensive therapy were prospectively enrolled into the study. After 10 days of placebo run-in period, they were randomized within the same group as cross-over design to one month carvedilol 25 mg and one month nebivolol 5 mg regimen given once daily in the morning. The primary outcome variables were systolic and diastolic blood pressures determined by 24-hour ambulatory blood pressure measurements. Mutlivariate analysis of variance for repeated measurements with 3x2 factorial design was used for statistical analysis of results. Results: The study group consisted of 6 women and 14 men whose mean age was 42.9±12.8 years (range 19-63 years). Mean heart rate was significantly decreased after commencing both carvedilol (70.2±5.2 bpm) and nebivolol (64.9±3.9 bpm) treatments compared to placebo (78.8±5.2 bpm) (p<0.05). Both carvedilol (133.8±9/86.6±8.6 mmHg) and nebivolol (134±8.7/85.6±7.4 mmHg) significantly decreased mean systolic and diastolic blood pressures compared to placebo (143.9±8.9/94.4±9.2 mmHg), respectively (p<0.05). However, there was no significant difference in decreasing either systolic or diastolic blood pressure between nebivolol and carvedilol therapies (p>0.05). No side effects were recorded during both carvedilol and nebivolol treatments. Conclusion: Although both carvedilol and nebivolol effectively decreased blood pressure compared to placebo, they showed similar efficacy for lowering blood pressure.

Keywords: Hypertension, nebivolol, carvedilol, beta-blocker


Okan Erdoğan, Bülent Ertem, Armağan Altun. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. Anatol J Cardiol. 2011; 11(4): 310-313


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2019 Turkish Society of Cardiology